Baekje Shenzhou Baiyue Ze has received FDA accelerated approval for the treatment of recurrent or refractory follicular lymphoma
小新11
发表于 2024-3-10 20:06:33
3787
0
0
Recently, BeiGene announced that Baiyue Ze& Reg; Zebutinib has been granted accelerated approval by the US Food and Drug Administration (FDA) for use in combination with the anti-CD20 monoclonal antibody Otuzumab to treat adult patients with recurrent or refractory (R/R) follicular lymphoma (FL) who have undergone at least second-line systemic treatment. This approval also marks the approval of the fifth indication for B-cell malignancy by Baiyue Ze in the United States.
Mehrdad Mobasher, Chief Medical Officer of Haematology at Baekje, said, "The accelerated approval of Baekje is of great significance as it provides the first and only BTK inhibitor treatment option for American follicular lymphoma patients who have failed initial treatment or have relapsed.". Baiyue Ze is the only BTK inhibitor that has shown efficacy in this type of malignant tumor to date. It has been approved for five tumor indications and has the widest coverage of indications among similar drugs worldwide. This fully demonstrates the differentiated clinical characteristics of Baiyue Ze, as well as our unwavering determination to bring this important treatment option to patients worldwide
Baiyue Ze has been approved for multiple indications in 70 markets worldwide, including the United States, the European Union, the United Kingdom, Canada, Australia, China, South Korea, and Switzerland, and is currently developing more indications worldwide. As of now, the Baiyue Ze Global Clinical Development Project has enrolled over 5000 participants in 29 countries and regions.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Company Review | BeiGene has suffered continuous losses in the past 7 years, and its stock price is under pressure. Can the new CFO bring a turning point?
- More than 40% reduction in losses in the first half of the year, but multiple peers have achieved profits. BeiGene is facing increasing peer pressure
- AbbVie sues for infringement again, BeiGene denies allegations: this move is intended to prevent project development
- Domestic innovative drug leader faces another 'patent challenge': AbbVie accuses BTK degradation agent of infringement, causing BeiGene's stock price to suffer a setback
- BeiGene denies AbbVie's accusation of "stealing trade secrets": will launch a firm defense and development projects will not be interrupted as a result
- BeiGene responds to AbbVie's lawsuit alleging theft of trade secrets: with the intention of obstructing the development process
- BeiGene executive Yin Min is under investigation after previously serving at AstraZeneca | News
- A senior executive of BeiGene has been investigated, and insiders say that the reason for the investigation is unrelated to BeiGene
- BeiGene executive Yin Min is suspected of smuggling and cooperating with the investigation
- Puyin International: downgraded BeiGene A-share rating to 'hold', maintaining target price of 181 yuan
-
11月21日、2024世界インターネット大会烏鎮サミットで、創業者、CEOの周源氏が大会デジタル教育フォーラムとインターネット企業家フォーラムでそれぞれ講演、発言したことを知っている。周源氏によると、デジタル教 ...
- 不正经的工程师
- 昨天 16:36
- 支持
- 反对
- 回复
- 收藏
-
アリババは、26億5000万ドルのドル建て優先無担保手形と170億元の人民元建て優先無担保手形の定価を発表した。ドル債の発行は2024年11月26日に終了する予定です。人民元債券の発行は2024年11月28日に終了する予定だ ...
- SOGO
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
スターバックスが中国事業の株式売却の可能性を検討していることが明らかになった。 11月21日、外国メディアによると、スターバックスは中国事業の株式売却を検討している。関係者によると、スターバックスは中国事 ...
- 献世八宝掌
- 前天 16:29
- 支持
- 反对
- 回复
- 收藏
-
【意法半導体CEO:中国市場は非常に重要で華虹と協力を展開】北京時間11月21日、意法半導体(STM.N)は投資家活動の現場で、同社が中国ウェハー代工場の華虹公司(688347.SH)と協力していると発表した。伊仏半導体 ...
- 黄俊琼
- 前天 14:29
- 支持
- 反对
- 回复
- 收藏